Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mycophenolate mofetil + voclosporin
- Development stage
- Phase 2
- Lead developer
- Aurinia
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination immunosuppressive therapy consisting of mycophenolate mofetil and voclosporin. Mycophenolate mofetil is a prodrug that converts to mycophenolic acid (MPA), which inhibits inosine monophosphate dehydrogenase (IMPDH), preventing T-cell and B-cell proliferation. Voclosporin is a calcineurin inhibitor that forms a heterodimeric complex with cyclophilin A to inhibit calcineurin, a calcium-dependent phosphatase involved in cytokine generation and T-cell activation. This combination is primarily used for treating active lupus nephritis, with clinical trials showing superior efficacy compared to mycophenolate mofetil alone.
02
Targets
Beyond the preview
Go deeper on mycophenolate mofetil + voclosporin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mycophenolate mofetil + voclosporin.